An activating intragenic deletion in NOTCH1 in human T-ALL

Blood

Volumn 119, Issue 22, 2012, Pages 5211-5214

  Haydu, J Erika ^a   De Keersmaecker, Kim ^b,c   Duff, Mary Kaye ^a   Paietta, Elisabeth ^d,e   Racevskis, Janis ^d   Wiernik, Peter H ^d   Rowe, Jacob M ^f   Ferrando, Adolfo ^a,g  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f RAMBAM MEDICAL CENTER   (Israel)

^g NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; NOTCH1 RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ARTICLE; CHROMOSOME REARRANGEMENT; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE DELETION; GENE LOCUS; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL;

EID: 84861842411     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-388504     Document Type: Article

References (16)

1. Ferrando AA, Look AT. Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. Semin Hematol. 2000;37(4):381-395.
2. Ferrando AA, Look AT. Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol. 2003;40(4):274-280.
3. Paganin M, Ferrando A. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev. 2011;25(2):83-90.
4. Aster JC, Blacklow SC, Pear WS. Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol. 2011;223(2):262-273.
5. Palomero T, Barnes KC, Real PJ, et al. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors. Leukemia. 2006;20(7):1279-1287.
6. Sulis ML, Williams O, Palomero T, et al. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood. 2008;112(3):733-740.
7. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269-271.
8. Ferrando AA. The role of NOTCH1 signaling in T-ALL. Hematology Am Soc Hematol Educ Program. 2009;2009:353-361.
9. Lobry C, Oh P, Aifantis I. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med. 2011;208(10):931-1935.
10. Liu H, Chiang MY, Pear WS. Critical roles of NOTCH1 in acute T-cell lymphoblastic leukemia. Int J Hematol. 2011;94(2):118-125.
11. Koch U, Radtke F. Notch in T-ALL: new players in a complex disease. Trends Immunol. 2011;32(9):434-442.
12. Radtke F, Wilson A, Stark G, et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity. 1999;10(5):547-558.
13. Malecki MJ, Sanchez-Irizarry C, Mitchell JL, et al. Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes. Mol Cell Biol. 2006;26(12):4642-4651.
14. Tsuji H, Ishii-Ohba H, Ukai H, Katsube T, Ogiu T. Radiation-induced deletions in the 5′ end region of Notch1 lead to the formation of truncated proteins and are involved in the development of mouse thymic lymphomas. Carcinogenesis. 2003;24(7):1257-1268.
15. Ashworth TD, Pear WS, Chiang MY, et al. Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood. 2010;116(25):5455-5464.
16. Jeannet R, Mastio J, Macias-Garcia A, et al. Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL. Blood. 2010;116(25):5443-5454.